Alendronate-induced hepatocellular lesion;Lesión hepatocelular inducida por alendronato

Gastroenterologia y Hepatologia

Volumn 24, Issue 5, 2001, Pages 244-246

  De la Serna Higuera, C ^a   Perez Villoria A ^a   Rodriguez Gomez S J ^a   Martinez Moreno J ^a   Betancourt Gonzalez A ^a   Martin Arribas M I ^a  

^a HOSPITAL VIRGEN DE LA CONCHA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINOTRANSFERASE; BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; METABOLIC BONE DISEASE; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 0034979107     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5705(01)70164-1     Document Type: Article

References (17)

1. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro
2. Upper gastrointestinal toxicity of alendronate
3. Liver damage due to alendronate
4. Hepatitis after alendronate
5. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
6. Preclinical toxicity of bisphosphonates
7. Endoscopy comparison of esophageal and gastroduodenal effects of risendronate and alendronate in postmenopausal women
8. Clodronate as a cause of aminotransferase elevation
9. Alendronate, from the laboratory to the patient: Preclinical safety profile of alendronate
10. Farnesyl pyrophosphate syntase is the molecular target of nitrogen-containing bisphosphonates
11. Drug-induced liver disease
12. Management of drug-induced liver disease
13. International Consensus Meeting Working Group: Criteria of drug-induced liver disorders
14. Hepatotoxicity
15. Drug metabolism and hepatotoxicity
16. Drug induced hepatic disorders: Incidence, management and avoidance
17. La hepatotoxicidad por fármacos: La prevención como objetivo